摘要
目的 加强kallistatin(Kal)这一多功能内源性抗血管生成因子抗肿瘤活性。方法 将其他多个基因与Kal联合应用，利用脂质体将带有目的基因的质粒转染入内皮细胞和肿瘤细胞，分析多基因联合治疗对细胞特性的影响。结果 Kal对肺癌细胞A549、NCI-H446、SPC-A1都具抑制作用。Kal与Trail或vasostatin(Vas)联合，可加强对SPC-A1细胞的抑制作用，但三者联合该抑制作用并未进一步加强。Kal与angiostatin(Ang)、Vas 联合应用可显著增强对血管内皮细胞EVC304生长、迁移以及小管形成的抑制作用。结论 Kal基因可与多种类型的基因联合作用，增强对肿瘤细胞和血管内皮细胞的抑制作用，为肿瘤的多基因联合治疗提供了实验基础。
Abstract
OBJECTIVE Kallistatin (Kal) is a new endogenous anti-angiogenic factor. It also has a role in anti-inflammation and anti-oxidation. Moreover， it could directly inhibit the proliferation of cancer cells. The aim of this study is to enhance the activities of this multi-functional gene. METHODS Kal together with other genes was co-transfected into cells using lipofectamine 2000 (Lipo)， and the cell activities were measured via MTT， scratch， transwell and tube formation assays. RESULTS It was found that Kal could inhibit the growth of A549， NCI-H446 and SPC-A1 cells in vitro. The combination of Kal with Trail or vasostatin(Vas) improved the growth inhibitive effect on SPC-A1 cells， but the combination of these three genes failed to further enhance this phenomenon. Moreover， combination of Kal with angiostatin (Ang) or Vas， two other anti-angiogenic factors， enhanced the anti-cancer and anti-angiogenic activities of Kal for EVC304 cells. The combination of the three genes had the most significant activities. CONCLUSION The activities of Kal can be enhanced by using multigene co-transfenction. This study has provided valuable experimental data for the further application of cancer multigene therapy.
关键词
kallistatin /
抗血管形成 /
肺癌 /
基因治疗 /
非癌基因成瘾
{{custom_keyword}} /
Key words
kallistatin /
anti-angiogenesis /
lung cancer /
gene therapy /
non-oncogene addiction
{{custom_keyword}} /
王启钊 刁勇 吕颖慧 李招发 王立强 许瑞安.
多基因联合作用对kallistatin活性增强的研究[J]. 中国药学杂志, 2011, 46(23): 1805-1810
WNG Qi-zho;DIO Yong;L Ying-hui;LI Zho-f;WNG Li-qing;XU Rui-n.
Enhancing the Anti-Cancer Activities of Kallistatin via Multigene Co-Transfection[J]. Chinese Pharmaceutical Journal, 2011, 46(23): 1805-1810
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] CHAO J， CHAI K X， CHEN L M， et al. Purification， characterization， and distribution in normotensive and spontaneously hypertensive rats[J]. J Biol Chem， 1990， 265(27)： 16394-16401.
[2] ZHOU G X， CHAO L， CHAO J. Kallistatin： a novel human tissue kallikrein inhibitor. In： Purification， characterization， and reactive center sequence[J]. J Biol Chem， 1992， 267(36)： 25873-25880.
[3] MIAO R Q， AGATA J， CHAO L， et al. Kallistatin is a new inhibitor of angiogenesis and tumor growth[J]. Blood， 2002， 100(9)： 3245-3252.
[4] MIAO R Q， CHEN V， CHAO L， et al. Structural elements of kallistatin required for inhibition of angiogenesis[J]. Am J Physiol Cell Physiol， 284(6)： 1604-1613.
[5] DIAO Y， MA J， XIAO W， et al. Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin[J]. World J Gastroenterol， 2007， 13(34)： 4615-4619.
[6] TSE L Y， SUN X， JIANG H， et al. Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas[J]. J Gene Med， 2008， 10(5)： 508-517.
[7] DEVANI M， VECCHI M， FERRERO S， et al. Kallikrein-kinin system in inflammatory bowel diseases： Intestinal involvement and correlation with the degree of tissue inflammation[J]. Dig Liver Dis， 2005， 37(9)： 665-673.
[8] WANG C R， CHEN S Y， WU C L， et al. Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation[J]. Arthritis Rheum， 52(4)： 1319-1324.
[9] CHAO J， YIN H， YAO Y Y， et al. Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation[J]. Hum Gene Ther， 2006， 17(12)： 1201-1213.
[10] SHEN B， HAGIWARA M， YAO Y Y， et al. Salutary effect of kallistatin in salt-induced renal injury， inflammation， and fibrosis via antioxidative stress[J]. Hypertension， 2008， 51(5)： 1358-1365.
[11] HSIEH J L， SHEN P C， SHIAU A L， et al. Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection[J]. Hum Gene Ther， 2009， 20（2）： 147-158.
[12] HUANG X， WANG X， DONG H， et al. High level expression of recombinant human kallistatin in Pichia pastoris and its bioactivity[J]. Chin J Biotech(生物工程学报)， 2010， 26(2)： 249-255.
[13] JIANG X， LI H， QIAO H， et al. Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice[J]. Cancer Sci， 2009， 100(11)： 2226-2233.
[14] SUN X， KRISSANSEN G W， FUNG P W C， et al. Anti-angiogenic therapy subsequent to adeno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver[J]. Int J Cancer， 2005， 113(4)： 670-677.
[15] JIANG H， MENG Q， TAN H， et al. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas[J]. Int J Cancer， 2007， 121(2)： 416-424.
[16] SUN X， QIAO H， JIANG H， et al. Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors[J]. Cancer Gene Ther， 2005， 12(1)：35-45.
[17] XU R， SUN X， TSE L Y， et al. Long-term expression of angiostatin suppresses metastatic liver cancer in mice[J]. Hepatology， 2003， 37(6)：1451-1460.
[18] YAO L，PIKE S E，PITTALUGA S，et al. Antitumor activities of the angiogenesis inhibitors interferon -inducible protein-10 and the calreticulin fragment vasostatin[J]. Cancer Immunol Immunother， 2002， 51(7)： 358-366.
[19] YAO L， PIKE S E， SETSUDA J， et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12[J]. Blood， 2000， 96： 1900-1905.
[20] CAI K X， TSE L Y， LEUNG C， et al. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin[J]. Clin Cancer Res， 2008， 14(3)： 939-949.
[21] DIAO Y， MA J， LI X， et al. Construction and activity of recombinant adeno-associated virus expressing vasostatin[J]. Chin J Biotech(生物工程学报)， 2008， 24(11)： 1949-1954.
[22] FOLKMAN J. Angiogenesis： an organizing principle for drug discovery[J]. Nat Rev Drug Discov， 2007， 6(4)： 273-286.
[23] SHI J， ZHENG D， MAN K， et al. TRAIL： a potential agent for cancer therapy[J]. Curr Mol Med， 2003， 3(8)： 727-736.
[24] SHI J， ZHENG D， LIU Y， et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice[J]. Cancer Res， 2005， 65(5)： 1687-1692.
[25] MA H， LIU Y， LIU S， et al. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice[J]. Hepatology， 2005， 42(6)： 1355-1363.
[26] MA H， LIU Y， LIU S， et al. Recombinant adeno-associated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors[J]. Int J Cancer， 2005， 116(2)： 314-321.
[27] LUO J， SOLIMINI N L， ELLEDGE S J. Principles of cancer therapy： oncogene and non-oncogene addiction[J]. Cell， 2009， 136(5)：823-837. Erratum in： Cell， 2009， 138(4)：807.
[28] SOLIMINI N L， LUO J， ELLEDGE S J. Non-oncogene addiction and the stress phenotype of cancer cells[J]. Cell， 2007， 130(6)： 986-988.
[29] WEINSTEIN I B， JOE A. Oncogene addiction[J]. Cancer Res， 2008， 68（9）： 3076-3080.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(2023 KB)
